参考文献/References:
[1] Yu L, Lv JC, Zhou XJ, Abnormal expression and dysfunction of novel SGLT2 mutations
identified in familial renal glucosuria patients[J]. Hum Genet,2011,129(3):335-344. DOI:
10.1007/s00439-010-0927-z.
[2] Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes[J].Lancet
Diabetes Endocrinol,2013,1(2):140-151. DOI: 10.1016/S2213-8587(13)70050-0.
[3] Bode B, Stenlöf K, Harris S,et al. Long-term efficacy and safety of canagliflozin over
104 weeks in patients aged 55-80 years with type 2 diabetes[J].Diabetes Obes Metab,2015,17
(3):294-303. DOI: 10.1111/dom.12428.
[4] Nigro SC, Riche DM, Pheng M, et al. Canagliflozin, a novel SGLT2 inhibitor for treatment of
type 2 diabetes[J].Ann Pharmacother,2013,47(10):1301-1311.DOI:10.1177/1060028013503626.
[5] Inagaki N, Kondo K, Yoshinari T, et al. Efficacy and safety of canagliflozin in Japanese
patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study
[J].Diabetes Obes Metab,2013,15(12):1136-1145. DOI: 10.1111/dom.12149.
[6] Bell DS. The potent synergistic effects of the combination of liraglutide and canagliflozin
on glycemic control and weight loss[J].Am J Case Rep,2014,15:152-154. DOI: 10.12659/AJCR.890626.
[7] Strojek K, Yoon KH, Hruba V, et al. Effect of dapagliflozin in patients with type 2
diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-
blind, placebo-controlled trial[J].Diabetes Obes Metab,2011,13(10):928-938. DOI: 10.1111/j.1463
-1326.2011.01434.x.
[8] Kaku K, Inoue S, Matsuoka O,et al. Efficacy and safety of dapagliflozin as a monotherapy
for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II
multicentre, randomized, double-blind, placebo-controlled trial[J].Diabetes Obes Metab,2013,15
(5):432-440. DOI: 10.1111/dom.12047.
[9] Schumm-Draeger PM, Burgess L, Korányi L,et al. Twice-daily dapagliflozin co-administered
with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial
[J].Diabetes Obes Metab,2015,17(1):42-51. DOI: 10.1111/dom.12387.
[10] Reilly TP, Graziano MJ, Janovitz EB,et al. Carcinogenicity risk assessment supports the
chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the
treatment of type 2 diabetes mellitus[J].Diabetes Ther,2014,5(1):73-96. DOI: 10.1007/s13300-014
-0053-3.
[11] Ferrannini E, Seman L, Seewaldt-Becker E,et al. A Phase IIb, randomized, placebo-controlled
study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes[J].Diabetes Obes
Metab,2013,15(8):721-728. DOI: 10.1111/dom.12081.
[12] Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control
as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2
diabetes: a 24-week, randomized, placebo-controlled trial[J].Diabetes Obes Metab,2014,16(2):147
-158. DOI: 10.1111/dom.12188.
[13] Wilding JP, Ferrannini E, Fonseca VA,et al. Efficacy and safety of ipragliflozin in
patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study
[J].Diabetes Obes Metab,2013,15(5):403-409. DOI: 10.1111/dom.12038.
[14] Seino Y, Sasaki T, Fukatsu A,et al. Dose-finding study of luseogliflozin in Japanese
patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled,
phase II study[J].Curr Med Res Opin,2014,30(7):1231-1244. DOI: 10.1185/03007995.2014.909390.
[15] Seino Y, Sasaki T, Fukatsu A, et al. Efficacy and safety of luseogliflozin monotherapy in
Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled,
phase Ⅱ study[J].Curr Med Res Opin,2014,30(7):1219-1230.DOI:10.1185/03007995.2014.901943.
[16] Kaku K, Watada H, Iwamoto Y, et al. Efficacy and safety of monotherapy with the novel
sodium/glucose cotransporter-2 inhibitor to fogliflozin in Japanese patients with type 2
diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind,
parallel-group comparative study[J].Cardiovasc Diabetol,2014,13:65. DOI: 10.1186/1475-2840-13-
65.
[17] Nyirjesy P, Sobel JD, Fung A, et al. Genital mycotic infections with canagliflozin, a
sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled
analysis of clinical studies[J].Curr Med Res Opin,2014,30(6):1109-1119. DOI:
10.1185/03007995.2014.890925.
[18] Nicolle LE, Capuano G, Ways K, et al. Effect of canagliflozin, a sodium glucose co-
transporter 2(SGLT2)inhibitor, on bacteriuria and urinary tract infection in subjects with type
2 diabetes enrolled in a 12-week, phase 2 study[J].Curr Med Res Opin,2012,28(7):1167-1171. DOI:
10.1185/03007995.2012.689956.
[19] Nagata T, Fukuzawa T, Takeda M, et al. Tofogliflozin, a novel sodium-glucose co-transporter
2 inhibitor, improves renal and pancreatic function in db/db mice[J].Br J Pharmacol,2013,170
(3):519-531. DOI: 10.1111/bph.12269.
[20] Johnsson KM, Ptaszynska A, Schmitz B,et al. Urinary tract infections in patients with
diabetes treated with dapagliflozin[J].J Diabetes Complications,2013,27(5):473-478. DOI:
10.1016/j.jdiacomp.2013.05.004.
[21] Johnsson KM, Ptaszynska A, Schmitz B, et al. Vulvovaginitis and balanitis in patients with
diabetes treated with dapagliflozin[J].J Diabetes Complications, 2013, 27(5):479-484. DOI:
10.1016/j.jdiacomp.2013.04.012.
[22] Reilly TP, Graziano MJ, Janovitz EB, et al. Carcinogenicity risk assessment supports the
chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the
treatment of type 2 diabetes mellitus[J].Diabetes Ther,2014,5(1):73-96. DOI: 10.1007/s13300-014
-0053-3.
[23] Lin HW, Tseng CH. A review on the relationship between SGLT2 inhibitors and cancer[J]. Int
J Endocrinol,2014,2014:719578. DOI: 10.1155/2014/719578.
[24] Ljunggren Ö, Bolinder J, Johansson L, et al. Dapagliflozin has no effect on markers of
bone formation and resorption or bone mineral density in patients with inadequately controlled
type 2 diabetes mellitus on metformin[J].Diabetes Obes Metab, 2012,14(11):990-999. DOI:
10.1111/j.1463-1326.2012.01630.x.
[25] Foote C, Perkovic V, Neal B. Effects of SGLT2 inhibitors on cardiovascular outcomes[J].Diab
Vasc Dis Res,2012,9(2):117-123. DOI: 10.1177/1479164112441190.
相似文献/References:
[1]曾静波,王姮.2型糖尿病与自身免疫反应[J].国际内分泌代谢杂志,2007,(04):259.
[2]朱素君,谢锦桃,刘军,等.二甲双胍：2型糖尿病治疗的基础药[J].国际内分泌代谢杂志,2007,(04):280.
[3]刘艳清 易秋艳 邵加庆.肠道菌群与肥胖和糖尿病的关系[J].国际内分泌代谢杂志,2015,(01):31.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.007]
Liu Yanqing,Yi Qiuyan,Shao Jiaqing..Relationship between gut microbiota, obesity and diabetes[J].International Journal of Endocrinology and Metabolism,2015,(05):31.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.007]
[4]姚旻 赵爱源 张宏.肠道菌群与2型糖尿病[J].国际内分泌代谢杂志,2015,(01):35.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.008]
Yao Min*,Zhao Aiyuan,Zhang Hong..Relationship between gut microbiota and type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2015,(05):35.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.008]
[5]赵丽娟,徐宽枫,杨涛,等.SLC30A8和PTPRD基因多态性与南京地区中老年人群2型糖尿病的相关性研究[J].国际内分泌代谢杂志,2015,(03):145.[doi:10.3760/cma.j.issn.1673-4157.2015.03.001]
Zhao Lijuan*,Xu Kuanfeng,Yang Tao,et al.Relationship between SLC30A8 and PTPRD gene polymorphisms and type 2 diabetes in middle aged and elderly people in Nanjing area[J].International Journal of Endocrinology and Metabolism,2015,(05):145.[doi:10.3760/cma.j.issn.1673-4157.2015.03.001]
[6]王洁,何媛,于珮.糖尿病肾病的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
Wang Jie*,He Yuan,Yu Pei..Risk factors of diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(05):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
[7]刘帅,张萍,方毅,等.2型糖尿病合并无症状冠状动脉钙化的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):158.[doi:10.3760/cma.j.issn.1673-4157.2015.03.004]
Liu Shuai*,Zhang Ping,Fang Yi,et al.Analysis of the risk factors related with asymptomatic coronary calcification for type 2 diabetic patients[J].International Journal of Endocrinology and Metabolism,2015,(05):158.[doi:10.3760/cma.j.issn.1673-4157.2015.03.004]
[8]徐庆海,马颖,李铁马.2型糖尿病患者高甘油三酯血症-腰围表型与甲状腺功能异常的关系[J].国际内分泌代谢杂志,2015,(04):222.[doi:10.3760/cma.j.issn.1673-4157.2015.04.002]
Xu Qinghai,Ma Ying,Li Tiema..Association of hypertriglyceridaemic-waist phenotype with thyroid dysfunction in patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(05):222.[doi:10.3760/cma.j.issn.1673-4157.2015.04.002]
[9]潘道延,沈洁,朱筱,等.利格列汀对2型糖尿病大鼠代谢性内毒素血症的影响[J].国际内分泌代谢杂志,2015,(04):230.[doi:10.3760/cma.j.issn.1673-4157.2015.04.004]
Pan Daoyan,Shen Jie,Zhu Xiao,et al.Effects of linagliptin on metabolic endotoxemia in type 2 diabetic rats[J].International Journal of Endocrinology and Metabolism,2015,(05):230.[doi:10.3760/cma.j.issn.1673-4157.2015.04.004]
[10]黄桥,白洁,杜洪泉.一种新的脂肪细胞因子——cartonectin[J].国际内分泌代谢杂志,2015,(04):265.[doi:10.3760/cma.j.issn.1673-4157.2015.04.014]
Huang Qiao*,Bai Jie,Du Hongquan..A novel adipokine--cartonectin[J].International Journal of Endocrinology and Metabolism,2015,(05):265.[doi:10.3760/cma.j.issn.1673-4157.2015.04.014]